Kypha Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Later Stage VC
- Investors
-
7
Kypha General Information
Description
Developer in-vitro diagnostic biomarker tests intended to monitor immune system activity. The company's platform facilitates testing at scale from home health to clinical laboratories helping to detect the onset of adverse events earlier optimizing treatment sooner and delivering precise, real-time immune insights for informed treatment decisions, enabling patients to have a higher chance of favorable health outcomes.
Contact Information
Website
www.kypha.netCorporate Office
- 4340 Duncan Avenue
- Suite 204
- Saint Louis, MO 63110
- United States
Corporate Office
- 4340 Duncan Avenue
- Suite 204
- Saint Louis, MO 63110
- United States
Kypha Timeline
Kypha Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 01-Oct-2024 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series B) | 12-May-2022 | Completed | Generating Revenue | |||
| 7. Secondary Transaction - Private | 01-Sep-2020 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series A) | 26-Feb-2018 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2016 | Completed | Generating Revenue | |||
| 4. Seed Round | 01-Oct-2014 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 2. Grant | 01-Jan-2011 | $273K | $225K | Completed | Generating Revenue | |
| 1. Debt - General | 01-Jan-2010 | $225K | $225K | Completed | Startup |
Kypha Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | 13,157,889 | $0.001000 | $0.38 | $0.38 | 1x | $0.38 | 15.77% | |
| Seed | 25,652,737 | $0.001000 | $0.38 | $0.38 | 1x | $0.38 | 30.74% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Kypha Comparisons
Industry
Financing
Details
Kypha Competitors (17)
One of Kypha’s 17 competitors is Decipher Urologic Cancers, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Decipher Urologic Cancers | Formerly VC-backed | San Diego, CA | ||||
| Accelerate Diagnostics | Corporation | Tucson, AZ | ||||
| Circle Cardiovascular Imaging | Private Equity-Backed | Calgary, Canada | ||||
| Foundation Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Hain Lifescience | Corporate Backed or Acquired | Nehren, Germany |
Kypha Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kypha Patents
Kypha Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022271275-A1 | Target measurement | Pending | 07-May-2021 | ||
| CA-3216433-A1 | Target measurement | Pending | 07-May-2021 | ||
| EP-4334719-A1 | Target measurement | Pending | 07-May-2021 | ||
| US-20240288421-A1 | Target measurement | Pending | 07-May-2021 | ||
| US-11029318-B2 | Methods for predicting and treating patients with increased risk of adverse pregnancy outcome | Active | 28-Aug-2015 | A61K45/06 |
Kypha Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kypha Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Holton Capital Group | Asset Manager | Minority | ||
| StartUp Health | Venture Capital | Minority | ||
| St. Louis Arch Angels | Angel Group | Minority | ||
| BioGenerator Ventures | Venture Capital | Minority | ||
| Missouri Technology Corporation | Venture Capital | Minority |
Kypha Acquisitions (1)
Kypha’s most recent deal was a Merger/Acquisition with Biosensia. The deal was made on 13-Jul-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Biosensia | 13-Jul-2018 | Merger/Acquisition | Diagnostic Equipment |
Kypha FAQs
-
When was Kypha founded?
Kypha was founded in 2010.
-
Where is Kypha headquartered?
Kypha is headquartered in Saint Louis, MO.
-
What is the size of Kypha?
Kypha has 16 total employees.
-
What industry is Kypha in?
Kypha’s primary industry is Diagnostic Equipment.
-
Is Kypha a private or public company?
Kypha is a Private company.
-
What is Kypha’s current revenue?
The current revenue for Kypha is .
-
How much funding has Kypha raised over time?
Kypha has raised $15.5M.
-
Who are Kypha’s investors?
Holton Capital Group, StartUp Health, St. Louis Arch Angels, BioGenerator Ventures, and Missouri Technology Corporation are 5 of 7 investors who have invested in Kypha.
-
Who are Kypha’s competitors?
Decipher Urologic Cancers, Accelerate Diagnostics, Circle Cardiovascular Imaging, Foundation Medicine, and Hain Lifescience are some of the 17 competitors of Kypha.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
